(lp0
S'Alkermes plc  to Present Data on Two-Month Dosing Option of ARISTADA at ... StreetInsider.com - Mar 20, 2017 Alkermes plc  today announced that data for the two-month dosing option of ARISTADA  extended-release injectable suspension for the treatment of schizophrenia will be presented at the 16th International Congress&nbsp;...'
p1
aS"Alkermes Plc  Q4 2016 Results - Earnings Call Transcript Seeking Alpha - Feb 15, 2017 Good morning, and welcome to the Alkermes' Fourth Quarter and Year End 2016 Financial Results. My name is Brandon, and I'll be your operator for today.Alkermes plc  Tops Q4 EPS by 11c - StreetInsider.comFederated Investors Inc. PA Holds Stake in Alkermes PLC  - The Cerbat Gem"
p2
aS'Institutions Peg This Stock As a Favorite: Alkermes plc  Midway Monitor - 9 hours ago Based on the lastest quarterly filings, institutions continue to be large stakeholders in Alkermes plc . The big banks are holding 98.80% of the shares while company insiders are clinging to 0.80%.FY2018 EPS Estimates for Alkermes Plc Cut by Analyst  - Chaffey BreezeAlkermes Plc  Insider Sells $361860.30 in Stock - The Cerbat Gem'
p3
aS'Alkermes PLC: Sales Rise, Losses Fall, and the Pipeline Moves Forward Motley Fool - Nov 7, 2016 Alkermes , a biopharmaceutical company that specializes in extended-release drug delivery technology, reported third-quarter results on Nov. 2 and provided investors with an update on its pipeline.'
p4
aS"Why Alkermes PLC Skyrocketed Today Motley Fool - Oct 21, 2016 Alkermes tested ALKS 5461 in patients with major depressive disorder who haven't been helped by other drugs. At the higher dose, ALKS 5461 improved symptoms of depression -- based on two different scales used by doctors -- compared with placebo.Analysts Change Price Targets for Two Biotech Stocks: Alkermes Plc (ALKS ... - Smarter AnalystAlkermes plc  Announces Third ALKS 5461 Phase 3 Met Primary Endpoint in MDD - StreetInsider.com"
p5
aS'Analyst Activity  Cantor Fitzgerald Reiterates Hold on Alkermes Plc  Market Exclusive - Mar 16, 2017 Today, Cantor Fitzgerald reiterated its Hold rating on Alkermes Plc  with a price target of $51.00. There are 3 hold ratings, 7 buy ratings on the stock.Alkermes Starts Phase III Study to Treat Multiple Sclerosis - Yahoo Finance'
p6
aS"Investors Are Missing An Opportunity With Alkermes Seeking Alpha - Feb 27, 2017 We remain bullish on Alkermes  because of their substantial and growing revenue and their healthy pipeline of valuable assets.Alkermes' Corporate Presentation to be Webcast at the Cowen and Company 37 - Business Wire Bullish Sweepers and Large Money Flow Witnessed in Alkermes plc  - Highland Mirror"
p7
aS'PRIMECAP Management Buys AstraZeneca PLC, Alkermes PLC, Whirlpool, Sells Union ... Nasdaq - Feb 14, 2017 PRIMECAP Management added to the holdings in Alkermes PLC by 102.19%. The purchase prices were between $42.3 and $59.5, with an estimated average price of $53.46.'
p8
aS"Alkermes plc Reports Third Quarter 2016 Financial Results Business Wire  - Nov 2, 2016 DUBLIN----Alkermes plc  today reported financial results for the third quarter of 2016. Our third quarter results demonstrate the value of our highly-diversified commercial portfolio, and were driven by the strong growth ...Alkermes'  CEO Richard Pops on Q3 2016 Results - Earnings Call Transcript - Seeking Alpha"
p9
aS"Alkermes Plc  Richard Pops on Q2 2016 Results - Earnings Call Transcript Seeking Alpha - Jul 28, 2016 Good morning ladies and gentlemen, and thank you for standing by. Welcome to the Alkermes Conference Call to discuss the Company's Second Quarter Financial Results.Alkermes plc Reports Second Quarter 2016 Financial Results - Business Wire Alkermes  Posts Narrower Q2 Loss, Ups 2016 Outlook - Zacks.com"
p10
a.